ABILIFY MAINTENA ER 300 MG VL

What it is

ABILIFY MAINTENA ER 300 MG VL is how the CMS NADAC file names this product. The FDA NDC Directory lists it as aripiprazole, under the trade name “ABILIFY MAINTENA”.

FDA gives its dosage form as kit.

The labeler, the company named on the label, is Otsuka America Pharmaceutical, Inc.

FDA lists no Established Pharmacologic Class for it.

The NADAC file of 2026-10-14 prices it under 3 NDCs (National Drug Codes); the FDA directory lists 1 of them.

NADAC classes it as a brand-name drug (rate-setting class B), and does not mark it as sold over the counter.

What pharmacies pay

Pharmacies pay $2,141.15 for 1 unit (EA) (1 × $2,141.14811 per EA, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.

NADAC’s explanation code for it: 1, calculated from the most recently completed pharmacy survey.

What NADAC measures · NADAC explanation codes

All 3 NDCs

• 59148-0018-70 · not listed as a package in the FDA directory · $2,141.14811 per EA · eff. 2026-09-23 filed
• 59148-0018-71 · not listed as a package in the FDA directory · $2,141.14811 per EA · eff. 2026-09-23 filed
• 59148-0232-12 · Otsuka America Pharmaceutical, Inc. · $2,141.14811 per EA · eff. 2026-09-23 filed

Other strengths, forms and brands

20 other products in the NADAC file share the FDA nonproprietary name aripiprazole with ABILIFY MAINTENA ER 300 MG VL.

Part D is one average per brand and generic name, over every strength and form.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18

OpenBill calculation · october-2026-medicare-part-b-payment-limit-files-final.zip + october-2026-ndc-hcpcs-crosswalk-final.zip · Part B limit 2026-10-01 to 2026-12-31 (file of 2026-09-17, retrieved 2026-10-18) · Part B crosswalk 2026-10-01 to 2026-12-31 (file of 2026-09-17, retrieved 2026-10-18)

What Medicare paid

Medicare Part B’s payment limit for HCPCS J0401, for 2026-10-01 to 2026-12-31, comes to $2,236.80 for 1 unit (EA), or $2,236.80 per EA once converted to NADAC’s unit for this product.

Medicare Part B pays for a drug like this only in specific settings, such as a drug given in a clinic or doctor’s office or used with certain medical equipment; most prescriptions filled at a pharmacy are paid by Part D.

The patient’s share under Part B (coinsurance, 20% of the limit, before deductibles and other coverage) is $1.4912 per 1 MG.

1 of the product’s 3 NDCs have this Medicare figure; the other 2 do not, and the interactive card says why for each.

Medicare's price is not your price.

What the Part B payment limit is · Converting it to the NADAC unit · How the spread is worked out

What to ask at the counter

None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.

• What is your cash price for 1 unit (EA)? Is it lower than what I would pay through my insurance?
• If you have Medicare Part B: is this drug covered for me in this setting, and what is my share?
• These are questions about price, not medical advice. Do not change or stop a medicine without talking to your prescriber or pharmacist.